共 50 条
- [21] Efficacy and Safety of Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) and Pioglitazone (PIO) Over 52 Weeks[J]. DIABETES, 2013, 62 : A284 - A284Forst, ThomasGuthrie, RobertGoldenberg, RonaldYee, JacquelineVijapurkar, UjjwalaMeininger, GaryStein, Peter
- [22] Efficacy and Safety of Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) Over 52 Weeks[J]. DIABETES, 2013, 62 : A277 - A278Yale, Jean-FrancoisBakris, GeorgeCariou, BertrandIglesias, Javier NietoWajs, EwaFigueroa, KatherineJiang, JoelUsiskin, KeithMeininger, Gary
- [23] Empagliflozin (EMPA) as Add-on to Linagliptin (LINA) and Metformin in Patients with Type 2 Diabetes (T2DM): A 24-Week Randomized, Double-Blind, Double-Dummy, Parallel-Group Trial[J]. DIABETES, 2016, 65 : A295 - A295Softeland, EirikMeier, Juris J.Vangen, BenteToorawa, RobertMaldonado, MarioWoerle, Hans J.Broedl, Uli C.
- [24] Efficacy and Safety of Empagliflozin (EMPA) in Younger, Overweight/Obese Patients with Type 2 Diabetes (T2DM) with HbA1c ≥8%[J]. DIABETES, 2014, 63 : A280 - A281Merker, LudwigLund, Soren S.Hantel, StefanSalsali, AfshinKim, GabrielBroedl, Uli C.Woerle, Hans J.Hach, Thomas
- [25] Fixed dose combinations of empaglilozin/linagliptin for 52 weeks as add-on to metformin in subjects with type 2 diabetes[J]. DIABETOLOGIA, 2014, 57 : S7 - S7Patel, S.DeFronzo, R.Lewin, A.Liu, D.Kaste, R.Woerle, H. J.Broedl, U. C.
- [26] Effect of empagliflozin (EMPA) on diabetic ketoacidosis (DKA) in patients with type 2 diabetes (T2DM): pooled clinical trial data[J]. DIABETOLOGIA, 2016, 59 : S26 - S27Lund, S.Solimando, F.Kohler, S.Zeller, C.Kaspers, S.
- [27] Empagliflozin Monotherapy for 12 Weeks Improves Glycemic Control in Japanese Patients With Type 2 Diabetes (T2DM)[J]. DIABETES, 2013, 62 : A297 - A298Kadowaki, TakashiHaneda, MasakazuInagaki, NobuyaTaniguchi, AtsushiSakamoto, MasashiKoiwai, KazukiRattunde, HenningWoerle, Hans J.Broedl, Uli C.
- [28] Empagliflozin (EMPA) Compared with Glimepiride (GLIM) as Add-on to Metformin (MET) for 2 Years in Patients with Type 2 Diabetes (T2DM)[J]. DIABETES, 2014, 63 : A70 - A70Ridderstrale, MartinAndersen, Knut RobertZeller, CordulaKim, GabrielWoerle, Hans J.Broedl, Uli C.
- [29] Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials[J]. Advances in Therapy, 2018, 35 : 1009 - 1022Ralph A. DeFronzoChristopher LeeSven Kohler
- [30] Linagliptin (LINA) as Add-on to Empagliflozin (EMPA) and Metformin in Patients with Type 2 Diabetes (T2DM): Subgroup Analysis by Baseline Demographics in Two 24-Week Randomized, Double-Blind, Parallel-Group Trials[J]. DIABETES, 2016, 65 : A297 - A298Kis, Sanja GiljanovicKhunti, KamleshMaldonaldo, MarioDel Parigi, AngeloGoetz, SophiaLee, Christopher